Biotech company developing cutting-edge benchtop protein printing technologies, Nuclera has raised $42.5 million funding in Series B. The round saw the participation of new and existing institutional and strategic investors, including M&G, Amadeus Capital Partners, E Ink, RT Partners, Future Planet Capital, British Business Bank Future Fund, and G. K. Goh.
The eProtein desktop bioprinter will initially screen and print proteins for research and drug discovery customers, and the funding will also fast-track the company’s march towards developing an all-encompassing proteomics platform.
Headquartered in Cambridge, UK and Boston, Massachusetts, the startup’s desktop bioprinter is a rapid protein prototyping and discovery platform that enables protein printing in just 24 hours. Significantly faster than existing methods of protein synthesis, the eProtein bioprinter is powered by the company’s eDrop digital microfluidic technology.
Michael Chen, Co-founder and CEO of Nuclera said: “Our eProtein desktop bioprinter makes it easy for scientists to access the proteins they need in a single day rather than the weeks, months, or even years that it currently takes. The new funding is a strong vote of confidence in our mission to increase the accessibility of the drug discovery and general bio-innovation process.”
The technology has gained significant traction with customers in the pharmaceutical, biotech, agribiotech, and synthetic biology industries, which are already working with Nuclera to accelerate their innovation pipelines.
Earlier last month, Parisian life sciences technology company DNA Script raised $200 million in a Series C funding round to create a fully automated desktop DNA printer.